ArticleJournal of clinical medicine2019
Prediction of Chronic Atrophic Gastritis and Gastric Neoplasms by Serum Pepsinogen Assay: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Artificial Intelligence for the Prediction of Helicobacter Pylori Infection in Endoscopic Images: Systematic Review and Meta-Analysis Of Diagnostic Test Accuracy.Journal of medical Internet research · 2020Pooled it
- Pooled it
- Gastric Mucosa Cancer Risk: The Operative Link on Gastritis Assessment Staging System.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Screening for and surveillance of premalignant conditions of the stomach.Best practice & research. Clinical gastroenterology · 2025Review
- The oral-gut axis in chronic atrophic gastritis: current perspectives and integrated strategies.Frontiers in immunology · 2025Review
- Assessing gastric cancer risk using the OLGA and OLGIM systems in Republic of Moldova.Frontiers in medicine · 2025Article
- Cost-Effectiveness of Serum Pepsinogen as a Gastric Cancer Targeted Screening Strategy in the United States.Gastro hep advances · 2025Article
- Postprandial gastrin-17 level is a useful dynamic marker for atrophic gastritis.World journal of gastrointestinal endoscopy · 2024Article
- Proteomic and serological markers for diagnosing cardia gastric cancer and precursor lesions in a Chinese population.Scientific reports · 2024Article
- Daily Diet and Nutrition Risk Factors for Gastric Cancer Incidence in a Japanese Population.Gut and liver · 2024Article
- Review
- Evolving Concepts in Helicobacter pylori Management.Gastroenterology · 2024Review
- Novel biomarkers for early detection of gastric cancer.World journal of gastroenterology · 2023Review
- Investigation of the prevalence and risk factors ofAnnals of medicine · 2023Article
- Assessment of Serum Pepsinogens with and without Co-Testing with Gastrin-17 in Gastric Cancer Risk Assessment-Results from the GISTAR Pilot Study.Diagnostics (Basel, Switzerland) · 2022Article
- Serum pepsinogen: A potential non-invasive screening method for moderate and severe atrophic gastritis among an asian population.Annals of medicine and surgery (2012) · 2022Article
- Factors Associated with False Negative Results in Serum Pepsinogen Testing for Precancerous Gastric Lesions in a European Population in the GISTAR Study.Diagnostics (Basel, Switzerland) · 2022Article
- [Helicobacter pylori-New aspects of forthcoming guidelines].Der Internist · 2022Review
- Brand interchangeability of pepsinogen tests in the real-world setting after eradication of Helicobacter pylori: a community-based study.BMC gastroenterology · 2022Article
- Analysis of Staged Features of Gastritis-Cancer Transformation and Identification of Potential Biomarkers in Gastric Cancer.Journal of inflammation research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Serum pepsinogen assay (sPGA), which reveals serum pepsinogen (PG) I concentration and the PG I/PG II ratio, is a non-invasive test for predicting chronic atrophic gastritis (CAG) and gastric neoplasms. Although various cut-off values have been suggested, PG I ≤70 ng/mL and a PG I/PG II ratio of ≤3 have been proposed. However, previous meta-analyses reported insufficient systematic reviews and only pooled outcomes, which cannot determine the diagnostic validity of sPGA with a cut-off value of PG I ≤70 ng/mL and/or PG I/PG II ratio ≤3. We searched the core databases (MEDLINE, Cochrane Library, and Embase) from their inception to April 2018. Fourteen and 43 studies were identified and analyzed for the diagnostic performance in CAG and gastric neoplasms, respectively. Values for sensitivity, specificity, diagnostic odds ratio, and area under the curve with a cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3 to diagnose CAG were 0.59, 0.89, 12, and 0.81, respectively and for diagnosis of gastric cancer (GC) these values were 0.59, 0.73, 4, and 0.7, respectively. Methodological quality and ethnicity of enrolled studies were found to be the reason for the heterogeneity in CAG diagnosis. Considering the high specificity, non-invasiveness, and easily interpretable characteristics, sPGA has potential for screening of CAG or GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.